Women’s cardiovascular care still leaves too many patients unheard
Cardiovascular disease remains the leading cause of death for women, and the gap between disease burden and clinical attention was the central concern at the MedTech Conference in Boston. Panelists returned to a common theme: women are still underdiagnosed, undertreated and too often forced to explain their symptoms more than once before receiving a diagnosis that should have come sooner. The discussion did not center on a single device or drug. It centered on the system failures that keep women from getting the right care at the right time.
The most direct opportunity, several panelists argued, begins with biology. Women experience cardiovascular disease through a different physiologic and social lens than men, and those differences are frequently flattened in practice into a one-size-fits-all model. Symptoms may not follow the classic male pattern clinicians were trained to recognize, which helps explain why a woman can arrive with genuine ischemic symptoms and leave without the urgency that would follow the same presentation in a man. Delay is not a minor administrative defect here. Delay changes myocardial injury, worsens outcomes and deepens distrust.
Inflammation may be the missing mechanistic thread
Dr. Kathleen Jordan, chief medical officer at Midi Health, pointed to inflammation research as one of the biggest unmet needs in women’s cardiovascular health. Her comments reflected a broader biologic premise: inflammation is not just a background marker, but a plausible driver of vascular injury, plaque instability and multi-organ disease burden. Women have higher rates of autoimmune disease, and inflammatory pathways also intersect with dementia, cancer and other chronic conditions that do not sit neatly in separate specialty silos.
The clinical relevance is hard to ignore. If inflammatory biology contributes to vascular dysfunction in women at higher rates or through different pathways, then cardiovascular prevention cannot rely only on traditional risk scoring and standard lipid-centric thinking. It may require better biomarkers, more phenotyping and a willingness to treat inflammation as a therapeutic target rather than a vague correlate. The science remains incomplete, but the clinical suspicion is already strong enough to justify more serious investment.
One sentence captured the tone of the panel: women’s inflammation is still a black box.
Listening changes outcomes before the procedure ever begins
Sarah Huoh, corporate vice president of public affairs at Edwards Lifesciences, pushed the discussion into a more immediate bedside reality. She described a woman who survived childhood cancer, later developed valve disease because of her cancer treatment and then faced major obstacles to surgery because prior radiation exposure complicated her options. The case illustrated how women can spend years navigating a system that recognizes risk only after the damage has accumulated.
Huoh’s point was not simply that access is uneven. It was that the healthcare system still asks women to self-advocate through layers of skepticism, especially when their clinical history is complex. Prior radiation exposure, prior cancer therapy and structural heart disease can make management far more difficult, but complexity should trigger deeper evaluation, not slower care. In a field that relies on precise imaging, procedural planning and multidisciplinary judgment, listening is not a soft skill. It is part of diagnosis.
When clinicians at the bedside are not heard, women are often left to repeat their story until it sounds severe enough to qualify for intervention. That is a harmful way to practice cardiovascular medicine, because it rewards persistence rather than pathology.
Trial representation still lags behind the population being treated
Alicia Chong Rodriguez, founder of Bloomer Tech, argued that women cannot remain an afterthought in clinical trials or in the companies building cardiovascular technologies. Her critique lands on a persistent problem in device development, drug testing and commercial strategy: the population most affected by the disease is not always the population most adequately represented in the evidence base.
Laura Mauri, senior vice president and chief scientific and medical officer at Medtronic, made the same point from the standpoint of scientific data quality. Women have historically been underrepresented in healthcare research, and Mauri said the industry needs to enrich the data and overrepresent women to close the gap. She extended the argument to women of color, for whom the evidence deficit is even more pronounced. The implication is simple: if a therapy, diagnostic tool or device is developed in a cohort that undercounts the people who will actually use it, the product may be well engineered yet still poorly matched to real-world care.
This is where clinical trial design intersects with market logic. An underrepresented population is not just an equity issue; it is a development risk. Endpoints can look cleaner than they should, safety signals can be harder to interpret and the downstream product strategy can miss the very patients most likely to benefit. Doubling down on women’s cardiovascular health is not charity. It is a rational response to a large, undertreated market with substantial unmet need.
Investment will follow evidence only if the evidence is built differently
The panel’s final message was less about inspiration than about infrastructure. More science on inflammation, better listening in clinical encounters, stronger women’s representation in trials and more committed capital were presented as connected priorities, not separate talking points. Women’s cardiovascular health has suffered from a familiar pattern: the evidence base is thin, the product pipeline is built around the thin evidence, and investment then follows the contours of that incomplete system.
Breaking that cycle requires researchers who ask different questions, companies that design for female physiology from the outset and investors willing to back an area that has been overlooked despite its size and urgency. The payoff is likely to show up first in earlier diagnosis, better risk stratification and fewer women forced to fight for the care that should have been automatic.
What remains unresolved is not whether the burden is real. It is how quickly the field will build the data, tools and clinical habits needed to match the scale of the problem.